<?xml version="1.0" encoding="UTF-8"?>
<p id="p0075">Lopinavir/ritonavir inhibit the human immunodeficiency virus type 1 protease and are used in the treatment of human immunodeficiency virus infection and AIDS. Reports of the potentially successful use of LPV/RTV in the treatment of MERS
 <xref rid="bib27" ref-type="bibr">
  <sup>27</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib28" ref-type="bibr">
  <sup>28</sup>
 </xref> and an ongoing clinical trial
 <xref rid="bib29" ref-type="bibr">
  <sup>29</sup>
 </xref> have led to hypotheses about its usefulness in treating COVID-19 and its widespread use with ribavirin in the management of COVID-19 in China. The reported efficacy has been varied, and in a mouse model of MERS, LPV/RTV was able to only slightly reduce viral load without impacting other disease parameters.
 <xref rid="bib10" ref-type="bibr">
  <sup>10</sup>
 </xref>
</p>
